Good morning, everyone. Nice to see you again. A mellow morning here on the Pharmalot corporate campus, where the short people are sleeping in, because the local schoolhouses are closed. This gives us time to brew that extra cup of desired stimulation and, of course, get organized for another busy day. So why delay? Here are a few tidbits to get us all started.And by the way, please tune in to our next webinar in which former CNBC reporter and public relations expert Mike Huckman next Thursday will talk about how pharma can cope with media coverage ( see this). Meanwhile, have a great day...
European Debt Crisis Hits Drug Prices Some More (Reuters)
Merck Receives Subpoena Over Marketing For Two Drugs (Dow Jones)
UK's NICE Rejects AstraZeneca Faslodex Breast Cancer Drug (Reuters)
J&J Remains Short Of Doxil Cancer Drug (Dow Jones)
Ranbaxy May Resolve FDA Dispute And Ship Generic Lipitor (Bloomberg News)
Mylan Pays $17.5M For Pfizer Version Of Advair (Pharma Times)
Pfizer To Push Prevnar Vaccine Beyond Large Chinese Cities (Reuters)
Roche Wins $1.7M In Property Tax Appeal (NorthJersey.com)
EDITOR'S NOTE: Please check this post for updates throughout the morning
sunrise pic thx to benimoto on flickr
1 Comment
RE 'Ranbaxy may ..." - but then again...
(From the Bloomberg piece) “Though it appears more confident that problems have been resolved, the situation remains unclear,” Credit Suisse Tokyo- based health-care analysts Fumiyoshi Sakai and Toshiyuki Tateno said in a report yesterday.
.... which means "they may NOT!" Still sounds like a coin toss to me